The people behind the project - DRIVE-AB

To Top

DRIVE-AB: The people behind the project An overview of DRIVE-AB work packages, leaders, and participants 10/10/2016

To Top

DRIVE-AB Leaders and Partners

Table of Contents

DRIVE-AB Work Package Overview ............................................................................................ 3

Work Package 1 - Creating the building blocks of economic models ........................................ 4

Work Package 1A ................................................................................................................................ 4

Leaders ............................................................................................................................................ 4

Academic Participants ..................................................................................................................... 5

EFPIA Participants ......................................................................................................................... 10

Work Package 1B .............................................................................................................................. 11

Leaders .......................................................................................................................................... 11

Academic Participants ................................................................................................................... 12


Work Package 1C .............................................................................................................................. 16

Leaders .......................................................................................................................................... 16



Work Package 2 - Create, test and validate new economic models ....................................... 21

Leaders .......................................................................................................................................... 21



Work Package 3A .............................................................................................................................. 33

Leaders .......................................................................................................................................... 33



Work Package 3B .............................................................................................................................. 35

Leaders .......................................................................................................................................... 35



To Top

To Top

DRIVE-AB Work Package Overview

To Top

Work Package 1 - Creating the building blocks of economic models

Work Package 1A Objective: Define “responsible” use of antibiotics

Leaders

Inge Gyssens Academic Lead Radboud University Medical Centre Prof Inge C Gyssens is an infectious diseases specialist living in Antwerp, Belgium. She has a clinical appointment at Jessa Ziekenhuis, Hasselt and a teaching and research position at Hasselt University. At Radboud University Nijmegen Medical Centre and Canisius Wilhelmina hospital she leads several research projects on immunogenetics of infectious diseases. She is involved in educational projects on antimicrobial stewardship. She is work package leader of the recently started Innovative Medicines Initiative (IMI) project DRIVE-AB (Driving Reinvestment in R&D and Responsible Antibiotic Use.

Elizabeth Hermsen

EFPIA Co-lead

MSD/Merck & Co. Ltd.

Dr Hermsen is the Head of Global Antimicrobial Stewardship at Merck & Co.

Ltd. and an Adjunct Associate Professor at the University of Nebraska Medical

Center, College of Pharmacy, in Omaha, Nebraska. Dr. Hermsen received her

Doctor of Pharmacy degree from the University of Nebraska Medical Center

followed by a pharmacy practice residency at The Nebraska Medical Center

and a fellowship in Infectious Diseases Research and masters in business

administration at the University of Minnesota. Dr. Hermsen developed and co-directed the

antimicrobial stewardship program at The Nebraska Medical Center and subsequently joined Cubist,

where she created and led the Antimicrobial Stewardship Outreach Group. Now, in her role at

Merck, she is responsible for creating and executing a strategy to advance patient-centered

antimicrobial stewardship through education, implementation, research, and advocacy.

To Top

Barry Eisenstein

EFPIA Co-lead

MSD/Merck & Co. Ltd.

Dr Barry Eisenstein, M.D., FACP, FIDSA, FAAM, received his MD from Columbia University followed by training in Internal Medicine and Infectious Diseases at the University of North Carolina. He has spent his career in academy and industry, serving as chief of the ID division at the University of Texas Health Sciences Center, San Antonio then as Professor and Chair of the Department of Microbiology and Immunology at the

University of Michigan. Following four years as VP, Lilly Research Labs, in charge of ID discovery and clinical development, he moved to Boston as VP of Science and Technology, Beth Israel Deaconess Medical Center and Professor of Medicine, Harvard Medical School. Since 2003 he has worked at Cubist Pharmaceuticals, where he helped lead the approval process for Cubicin at the FDA and is now Senior Vice President, Scientific Affairs. He is the author of more than 100 original papers, book chapters, and editorials, has edited several books on infectious diseases and microbiology. He was a past editor of both Infection and Immunity (1989-96) and Antimicrobial Agents and Chemotherapy (2004-14). In 2008 he provided testimony before the US Senate on, “Emergence of the Superbug: Antimicrobial Resistance in the U.S.”, and in both 2010 and 2012 before the US Congress hearings on antibiotic resistance that led to the passage of the GAIN Act. He co-chaired a 2010 FDA Workshop panel on endpoints and non-inferiority margins for antibiotic development, and was a panelist at a 2011 joint Pew/IDSA/PhRMA workshop on antibiotic resistance. He was recently a member of the Research Committee and of the Research on Resistance Working Group of the IDSA and chaired the PhRMA taskforce on “emerging pathogens”, a group that met twice in 2012 with FDA leadership to discuss ways to reduce ATB registration hurdles. He is presently a member of the FNIH Biomarkers Consortium on endpoints in bacterial infections, of the CTTI group working on expediting clinical trials for bacterial infection, of the Brookings Institution Council on Antibacterial Drug Development, and of the IMI DRIVE-AB work project in the EU.

Academic Participants

Niels Adriaenssens Participant University of Antwerp Dr N. Adriaenssens, MD, PhD is a certified general practitioner. He is part of a group practice located in Sint-Katelijne-Waver, Belgium. In 2012, he successfully defended his PhD thesis: Outpatient antimicrobial use in Europe. He is working at the University of Antwerp, Vaccine & Infectious Disease Institute, as a post-doc researcher and teaching-assistant. He was part of the management team of ESAC as clinical scientist ambulatory care and is actively involved in GRACE and e-bug. He is currently collaborating in TRACE, APRES and SATURN. He developed disease-specific antibiotic

prescribing quality indicators for primary care and successfully applied drug- specific antibiotic prescribing quality indicators.

To Top

Herman Goossens Partner University of Antwerp

Prof Herman Goossens, MD (1982), Clinical Microbiologist (1988), PhD in Medical Microbiology (1990), professor of Medical Microbiology at the University of Antwerp in Belgium (1992). He received research fellowships of the University of Geneva (1985-86), the University of Tokyo (1987), and the University of Utrecht (1988). Herman Goossens received several honours and awards, including the American APUA (Alliance for the Prudent Use of Antibiotics) award in 2006. He published more than 500 full

papers in peer-reviewed scientific journals. He is the founder and Chair of the Belgian Antibiotic Policy Co-ordination Committee (BAPCOC). He coordinates several European projects funded by DG Research, DG SANCO, IMI and ECDC, such as the European Surveillance of Antibiotic Consumption (ESAC) project (moved to ECDC in July 2011), Genomics to Combat Resistance against Antibiotics in Community-acquired LRTI in Europe (GRACE), Development of RApid Point-of-care test Platforms for Infectious Diseases (RAPP-ID), Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE), and LAB-Net of the Combating Bacterial Resistance in Europe project (COMBACTE). Herman Goossens was the organiser of the European Conference on Antibiotic Use in 2001 on behalf of the Belgian EU Presidency, of the International Workshop on Educational Campaigns regarding antibiotic resistance in 2004, of the European Workshop on indicators for quality prescribing in primary care in 2005, and of the European Conference on Health Care Associated Infections and Antibiotic Use in 2010 on behalf of the Belgian EU Presidency. He is the founder of the annual European Antibiotic Awareness Day (EAAD). Herman Goossens was elected chair of the Scientific Advisory Board of the Joint Programming Initiative on Antimicrobial Resistance by his peers. He received the Methusalem award of the Flemish government in 2008 for a period of 14 years. His main fields of research are antibiotic use and resistance, respiratory tract infections, developing rapid and point-of-care diagnostic tests, and biofilms. His professional goal is to bridge the gap between basic and clinical research, with a major focus on antibiotic resistance, to enhance the standard of healthcare, public health and professional standards, for the good of the public in large.He is a popular resource person and opinion leader, much sought after by local and international media for views on matters related to public health and infectious diseases.

Marlies Hulscher Participant Radboud University Medical Center

Prof Marlies Hulscher is a senior researcher at the Scientific Institute for Quality of Healthcare (IQ healthcare) of the Radboud University Medical Center, Nijmegen. The institute is internationally recognised for its expertise on implementation research in health care settings. Marlies Hulscher has 25 years’ experience in implementation research. As a PI she has performed numerous studies to define, measure and improve the quality of care for patients with infectious or inflammatory diseases.

Research themes include antimicrobial stewardship, infection prevention, and outbreak management. Studies focus on the development of quality indicators, the assessment of determinants (barriers and facilitators) of appropriate patient care, the development of implementation strategies, and the evaluation of their effectiveness to improve patient care. Marlies Hulscher has published more than 100 articles in peer-reviewed journals including many systematic reviews to summarize current international literature.

To Top

Benedikt Huttner Participant University of Geneva Dr Benedikt Huttner is an infectious disease physician at the Division of Infectious Diseases and the Infection Control Program of Geneva University Hospitals (HUG) in Geneva, Switzerland. Benedikt’s research focuses on antibiotic stewardship and antimicrobial resistance, in the inpatient and outpatient setting. He is also an infectious disease consultant and actively involved in antibiotic stewardship at HUG.

Bart-Jan Kullberg Participant Radboud University Medical Centre Prof BJ Kullberg is cochairing the Radboudumc Center for Infectious Diseases. He has served as the chair of the Fellowship and Postgraduate Education Programme for Infectious Diseases of the Netherlands Society for Internal Medicine. His research interest includes educational aspects in antimicrobial stewardship, in particular regarding antifungal therapy. He is a board member of the Dutch Working Party on Antibiotic Policy (SWAB). He is coordinating the educational activities of SWAB, including the

development of e-learning material and the national Antimicrobial Stewardship team courses 2013-2014.

Annelie Monnier

Participant

Radboud University Medical Centre

After obtaining her Master degree Biomedical sciences (specialization

Infection and Immunity & Management, Policy Analysis and

Entrepreneurship) from the University of Amsterdam, Annelie started her

PhD thesis program within DRIVE-AB WP1A in October 2014 at the

Radboud University Medical Center. Her PhD program will be supervised by prof. Inge Gyssens, prof.

Marlies Hulscher and prof. Bart Jan Kullberg.

Find out more: https://www.linkedin.com/in/anneliemonnier

https://www.linkedin.com/in/anneliemonnier

To Top

Céline Pulcini Partner University of Lorraine

Prof Céline Pulcini, MD, PhD, Professor in Infectious diseases in Nancy (France), is a member of ESGAP executive committee (ESCMID Study Group for Antibiotic Policies), she is also vice-president of the international association WAAAR (World Alliance Against Antibiotic Resistance) and member of the French National Antibiotic Plan (Ministry of Health). She has been doing research studies on the antibiotic stewardship topic for ten years and she has published more than 100 articles in peer-reviewed journals.

Find out more: https://scholar.google.fr/citations?user=92LhdmAAAAAJ&hl=fr&oi=ao

Jeroen Schouten Participant Radboud University Medical Centre Dr Jeroen Schouten is an intensivist at the Canisius Wilhelmina Hospital (CWZ) in Nijmegen, a large teaching hospital in the Netherlands. He was trained in Radboud University Medical Centre and UCLH London. He has a PhD in implementation research and infectious diseases (2006) and has a special interest in antibiotic stewardship. He is chief medical safety

officer at the CWZ , head of the Quality Committee and member of the Executive Committee of the “Nederlandsche Internisten Vereeniging” (the Dutch society of Internal Medicine). He is head of ICU research at CWZ, performing both industry driven and investigator initiated studies, mostly in the field of antimicrobials (e.g. PK/PD in echinocandines). He is affiliated to IQ healthcare and has been involved in many research projects concerning appropriateness of antibiotic use (e.g. quality indicators for complicated UTIs). He is actively involved in the implementation of a National Antibiotic Stewardship programme and has co-authored the Dutch Practice Guide for Antibiotic Stewardship and co-organised National Congresses and symposia on Antibiotic Stewardship.

Mirjana Stanic Participant University Hospital Rijeka

Mirjana Stanić graduated as a Medical Doctor in 2012 from the Zagreb School of Medicine and Mirjana is currently pursuing a residency in clinical pharmacology and toxicology at UHC Rijeka. Find out more:

https://scholar.google.hr/citations?user=1GWqvosAAAAJ&hl=hr

https://scholar.google.fr/citations?user=92LhdmAAAAAJ&hl=fr&oi=ao

https://scholar.google.hr/citations?user=1GWqvosAAAAJ&hl=hr

To Top

Gianpiero Tebano Participant University of Lorraine

Biography not available at this time.

Ann Versporten Participant University of Antwerp Ann Versporten is working at the Laboratory of Medical Microbiology of the University of Antwerp, Belgium. She has been responsible as project and data manager for a number of European projects on antimicrobial consumption. She was in charge of the data management for the last two years (up to 2011) of ESAC (European Surveillance of Antimicrobial

Consumption), after which the project was transferred to the ECDC (European Centre for Disease Prevention and Control) as ESAC-Net. She was in charge of 3 other European projects. One focused on antimicrobial consumption in outpatient settings (the appropriateness of prescribing antibiotics in primary health care in Europe with respect to antibiotic resistance project – APRES), one focused on antimicrobial consumption among 14 non-EU countries of the WHO European region, in close collaboration with the WHO/EUROPE; and another targeted antimicrobial consumption among hospitalized children (Antibiotic Resistance and Prescribing in European Children project – ARPEC).

From 2014 upwards, she mainly works on the hospital-based Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (GLOBAL-PPS), the antimicrobial resistance and causes of non-prudent use of antibiotics in human medicine project (ARNA) and the DRIVE-AB project. Her main field of interest is the epidemiology of antibiotic use and the methods to employ to express antibiotic use in order to enhance evidence base of inappropriate antibiotic prescribing.

Vera Vlahović-Palčevski Partner University Hospital Rijeka

Vera Vlahović-Palčevski is a full professor and a specialist in clinical pharmacology at the University of Rijeka Medical School and University Hospital Rijeka, Croatia. Her closest fields of interest are pharmacoepidemology and antimicrobial therapy. She is the editor of local Guidelines for Hospital Antibiotic Use and Guideleines for Ambulatory Antibiotic Use. Vera is also a member of the Hospital Infection

Control Committee and is actively involved in hospital antimicrobial stewardship program. She has been chairing hospital drug and therapeutics committee since 2000. Since 2002 she has been a member of the EuroDURG Executive Committee. Presently. Vera is also a chair of the National Drug Committee at the Croatian Health Insurance Institute and the Ministry of Health. recently she has been appointed a member of the WHO WHO International Working Group for Drug Statistics Methodology.

To Top

Veronica Zanichelli Participant University of Geneva Dr Veronica Zanichelli is a MD who recently completed the postgraduate programme in infectious diseases at Padua University, Italy. Before joining as a fellow the infection prevention and control team at the University Hospital of Geneva in October 2014, she did a year of basic research in the field of antiretroviral drug resistance at the AIDS centre of McGill University in Montréal.

EFPIA Participants

Andreas Karas Participant Astellas Pharma Europe Ltd.

Dr Andreas Karas is Senior Director Medical Affairs for Anti-infectives and Pain at Astellas Pharma EMEA since September 2012.He is a physician and medical microbiologist and obtained his medical and specialist training in South Africa. He has broad medical experience working in Africa, Europe and the USA and has been involved in the creation of two start-up

companies in health technology. Before joining Astellas he worked for the Health Protection Agency in Cambridge, UK for ten years, where he practiced at hospitals in the region including the role of infection control doctor. He had clinical lead roles for immunosuppressed patients and antifungal agents and was director of the pathology department.

He has published on epidemic dysentery, ESBL resistance, MRSA, C.difficile and anti-fungals. In the past he has developed a rapid diagnostic test for epidemic dysentery at the CDC in the USA, and a patented self-sampling HPV test for cervical cancer screening.

Nathalie Baillon-Plot Participant Pfizer Ltd. Dr Nathalie Baillon-Plot joined Pfizer in 2004 in France Medical Information Department. In 2009, she joined the Zyvox European Medical Team in Paris. In early 2011, she was appointed EU Zyvox Medical Director. She is currently Antibiotics Medical Director for Europe. Nathalie has a Medical Degree with a training in General Practice and additional training in Management and worked at other pharmaceutical companies before joining Pfizer. She has a various experience as she held a number of

different positions as a Sales Manager, Marketing Director for various therapeutic areas and for various countries.

To Top

Charles Knirsch Partner Pfizer Ltd.

Dr Charles Knirsch manages the clinical evaluation of the increasingly robust pipeline of therapeutic vaccine candidates in the early stages of vaccine research and development. Prior to this role, he was VP, Head of Clinical Research in the Specialty Care Business Unit that included leadership of the line activities of statistics, clinical pharmacology and the clinical therapeutic groups. Ch. Knirsch is an Infectious Diseases physician

and epidemiologist who has contributed to or led development teams that have successfully completed several NDAs on Pfizer’s anti-infective medicines and in other therapeutic areas. He has participated in many initiatives in the European Union and United States of America to address the lack of research and development in anti-infectives.

Abdel Oualim Participant Sanofi

Dr Abdel Oualim, Senior Project Director at Sanofi, obtained his Doctorate of Pharmacy at the University of Poitiers in France before moving on to work in project development and management from entry into development through submission and approval. Abdel has ten years of experience in leading project teams and data management in multiple therapeutic areas and has 5 years of clinical research operation experience.

Work Package 1B Objective: Set, communicate and revise public health priorities

Leaders

Yehuda Carmeli Academic Lead Tel Aviv Sourasky Medical Centre

Prof Yehuda Carmeli (MD, MPH), Professor in Medicine, Sackler School of Medicine, Tel Aviv University, head of the Division of Epidemiology at Tel Aviv Medical Center and head of the Israeli National Center for Antibiotic Resistance, Israeli Ministry of Health. He was trained in infectious diseases and in public health at Harvard University. He has over 200 peer-reviewed publications on antibiotic resistance and

hospital epidemiology in various journals (including JAMA, Circulation, Nature Microbiology, Archives of Internal Medicine, and Antimicrobial Agents and Chemotherapy). He serves at the editorial board of Clinical Infectious Diseases, Infection Control and Hospital Epidemiology, and Current Opinion in Infectious Diseases. He participated in the FP6 MOSAR project on the dissemination of antimicrobial resistance in rehabilitation centres and to the community, in the FP7 SATURN and R-GNOSIS projects, and in the AIDA project, all dealing with various aspects of antibiotic resistance and antibiotic use.

To Top


Yoni Almagor Participant Tel-Aviv Souraski Medical Center


Itzhak Benenson Participant University of Tel-Aviv


Primrose Beryl Participant University of Tüebingen After graduating in Indian System of Medicine, she completed her Masters and PhD in Epidemiology at Christian Medical College, Vellore, India. Her doctoral studies were based on a birth cohort study studying the natural history of rotavirus funded by the Wellcome Trust Trilateral Initiative for Infectious diseases. In 2010, she joined the Clinical Epidemiology research group at the Institute of Medical Biometry and Medical Informatics,

Freiburg University Medical Centre, Germany as a researcher where she worked on the methodological aspects of non-inferiority trials. She has been involved in the epidemiological aspects and statistical analyses of hospital based and community based research as well as systematic reviews and meta-analyses. Find out more: http://www.researchgate.net/profile/Primrose_Beryl_Gladstone

Shimrit Cohen Percia Participant Tel-Aviv Souraski Medical Center


Andrea Cona Participant University Hospital Tübingen


http://www.researchgate.net/profile/Primrose_Beryl_Gladstone

To Top

Noga Fallach Participant Tel-Aviv Souraski Medical Center


Panagiota Gkolia Participant University Hospital Tübingen


Ivgeny Kleiman Participant Tel-Aviv Souraski Medical Center


Parichehr Shamsrizi Participant University of Tüebingen Parichehr Shamsrizi was born and raised in Hamburg, Germany and is currently studying in her 4th year at University of Tübingen Medical School, Germany. Ms. Shamsrizi is currently undertaking a dissertation under the supervision of Professor Evelina Tacconelli titled “Clinical impact of bacterial resistance in hospitalized patients“. She takes a special interest in Internal Medicine and Infectiology.

Erez Silberstein Participant Tel-Aviv Souraski Medical Center


To Top

Evelina Tacconelli Partner University of Tüebingen Prof E. Tacconelli is Professor of Infectious Diseases at the Tübingen University, Tübingen, Germany. She has been Lecturer on Medicine at the Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA. She was the recipient of the award from the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) for research excellence. She is the ESCMID Professional Affair Officer for

Infectious Diseases and serves on the editorial board of Lancet Infectious Diseases, Journal of Antimicrobial Chemotherapy, and Clinical Microbiology and Infection. She has published more than 100 original articles in peer-reviewed journals. She has significant experience in systematic reviews and meta-analyses on epidemiological and clinical aspect of antimicrobial resistant infections and in participating in international projects.

Liz Temkin Participant Tel-Aviv Souraski Medical Center

Dr Elizabeth Temkin, MSN, DrPH, is an epidemiologist in the National Center for Infection Control of the Israeli Ministry of Health and in the epidemiology department at Tel Aviv Medical Center. She received a Master's degree from Yale School of Nursing and a doctorate from Johns Hopkins School of Public Health. She conducts research and surveillance regarding hospital-acquired infections, antibiotic use and antibiotic resistance.

Joyce Witt Participant Tel-Aviv Souraski Medical Center


To Top

EFPIA Participants

Kim A. Gilchrist Participant Glaxosmithkline

Dr. Gilchrist joined GlaxoSmithKline supporting the Alternative Discovery and Development and Infectious Disease area in the area, Value Evidence and Outcomes. She is a senior Health Outcomes Researcher, Board certified Internal Medicine Practitioner, and Microbiologist with 20 years’ experience in clinical teaching and pharmaceutical drug development. Her most recent infectious disease drug development focused on two antibacterials and two

HIV antiretroviral products (Dolutegravir, Efavirenz). Prior to joining GSK, she led the US Health Outcomes group at AstraZeneca overseeing a full portfolio of products within respiratory, cardiovascular, oncology and infectious disease. Her early career focused on all areas of clinical development, Medical Affairs, Medical Advertising review while at AstraZeneca, and Dupont Pharmaceuticals.

Christine Luxemburger Participant Sanofi


Karin Mörup Participant Astra Zeneca AB


Danielle Potter Participant Astra Zeneca AB


Shuvayu Sen Participant MSD/Merck & Co. Ltd.


To Top

Work Package 1C Objective: Develop antibiotic valuation models

Leaders

Ramanan Laxminarayan

Academic Lead

University of Strathclyde

Prof Ramanan Laxminarayan directs the Center for Disease Dynamics,

Economics & Policy. He is also a Senior Research Scholar and Lecturer at

Princeton University. His research deals with the integration

of epidemiological models of infectious diseases and drug resistance into

the economic analysis of public health problems. He has worked to

improve understanding of drug resistance as a problem of managing a

shared global resource.

Laxminarayan has worked with the World Health Organization (WHO) and the World Bank on evaluating malaria treatment policy, vaccination strategies, the economic burden of tuberculosis, and control of non-communicable diseases. He has served on a number of advisory committees at WHO, Centers for Disease Control and Prevention, and the Institute of Medicine. In 2003-04, he served on the National Academy of Science/Institute of Medicine Committee on the Economics of Antimalarial Drugs and subsequently helped create the Affordable Medicines Facility for malaria, a novel financing mechanism for antimalarials. His work has been covered in major media outlets including Associated Press, BBC, CNN, the Economist, LA Times, NBC,NPR, Reuters, Science, Wall Street Journal, and National Journal. Find out more: http://www.cddep.org/profile/ramanan_laxminarayan

John Rex EFPIA Lead AstraZeneca AB Dr John H. Rex, MD is Senior Vice President and Chief Strategy Officer for AstraZeneca Infection, a Non-Executive Director of F2G, Ltd. and Adenium Biotech ApS, Expert-in-Residence at the Wellcome Trust, and a member of the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria. Dr. Rex thus brings a global perspective to the challenge of AMR as well as both small and large pharmaceutical

company experience. He is one of two Industry-based cofounders of the Innovative Medicines Initiative’s New Drugs for Bad Bugs program bringing Industry and Academic collaborators together on a range of antibiotic discovery and development projects.

http://www.cddep.org/profile/ramanan_laxminarayan

To Top


Abby Colson Participant University of Strathclyde

Abby Colson is a resident scholar at CDDEP. She received a bachelor’s

degree in political science and environmental studies from American

University. Her past work focused on discussing the policy implications of

health research. She is now exploring methods to assess the economic

impact of public health foundations. Abby is interested in how policymakers

utilize research in their decision-making, especially when addressing health and environmental

issues. She enjoys dance, crosswords, and all water-related activities. Find out more:

http://www.cddep.org/profile/abigail_colson

Dusan Drabik

Participant

Wageningen University

Prof Dusan Drabik is an Assistant Professor of Agricultural Economics at

Wageningen University, the Netherlands, and a Research Associate at

LICOS Centre for Institutions and Economic Performance, University of

Leuven, Belgium. In his recent work, Dusan has analyzed the market and

environmental effects of alternative biofuel policies in the United States,

the European Union, and developing countries. Find out more:

https://sites.google.com/site/dusandrabik83/

Timo Goeschl Partner Heidelberg University

Prof Timo Goeschl is a Professor in the Department of Economics (Alfred

Weber-Institute) at Heidelberg University. He serves as Co-Editor of

Environmental and Resource Economics and as a Research Associate at the

Centre for European Economic Research (ZEW) in Mannheim. Before

Heidelberg, he was on the faculty of the University of Wisconsin-Madison

and the University of Cambridge. His research has been published in the

Journal of the European Economic Association, Public Choice, the Journal of

Regulatory Economics, the Journal of Environmental Economics and Management, Environmental

and Resource Economics and other outlets.

http://www.cddep.org/profile/abigail_colson

https://sites.google.com/site/dusandrabik83/

To Top

Axel Leporowski Participant Heidelberg University

Dr Axel Leporowski, MSc, works at the University of Heidelberg in Germany as researcher. He received his Medical Degree (M.D.) from the Panamerican University in Mexico. Afterwards, he worked in a clinic as the primary physician in an impoverished rural community, where he was in charge with the prevention, diagnosis and treatment of acute and chronic diseases. He co-authored an article entitled Acute Myeloid Leukemia treatment in the Elderly

Patient: A Meta-analysis. Afterwards, he decided to follow another passion of his, and attended Heidelberg University in Germany, where he studied health economics (Master of Science); his thesis evaluated the economic impact of chronic wounds. He can be contacted at [email protected]

Itamar Megiddo Participant University of Strathclyde

Itamar Megiddo is a research associate at CDDEP. He received both a bachelor's and a master's degree in economics from McGill University, where he worked on international environmental agreements. He currently works on individual based models in both fields of antibiotic resistance and malaria eradication. He has lived across the globe, however, as a native Israeli he appreciates the DC weather after living for four years in

Montreal. When he is not hard at work, you may find Itamar on the baseball field or on the basketball court. Find out more: http://www.cddep.org/profile/itamar_megiddo

Robyn Millar Participant (Administrative) University of Strathclyde

In July 2014, I graduated from the University of Strathclyde with a first class BA (Hons) degree in Management Science and Marketing. During my honours year, I conducted research on healthcare systems in both Northern Ireland and Scotland: "Comparative Healthcare Systems: An exploratory study into policy divergence in the devolved UK and its implications in terms of Scottish and Northern Irish health policy communities

and their respective waiting time performances". The research furthered my interest in the health policy field and has led to my current position as Research Assistant at the Strathclyde International Public Policy Institute/Centre for Health Policy. I am currently working on a project dealing with demographic structure in Scotland and the future impacts of a decreased working-age population. Aside from this work, I am currently a project administrator for DRIVE-AB. I hope to pursue PhD research this coming September with a focus on utilising systems mapping methods, developed in the field of business strategy, to map poverty cycles within the local Scottish context. This will serve as a framework for interpretation for decision-makers in terms of policy intervention implementation and its effectiveness within these local contexts.

mailto:[email protected]

mailto:[email protected]

http://www.cddep.org/profile/itamar_megiddo

To Top

Alec Morton Partner University of Strathclyde

Prof Alec Morton has degrees from the University of Manchester and the University of Strathclyde. He has worked for Singapore Airlines, the National University of Singapore, and the London School of Economics, has held visiting positions at Carnegie Mellon University in Pittsburgh, Aalto University in Helsinki, and the University of Science and Technology of China in Hefei, and has been on secondment at the National Audit Office. His main interests are in decision analysis and health economics, and he is one of the developers

of the STAR toolkit sponsored by the Health Foundation.

Alec has been active in the INFORMS Decision Analysis Society and the OR Society. He is on the Editorial Board of Decision Analysis and is an Associate Editor for the EURO Journal on Decision Processes, the Transactions of the Institute of Industrial Engineers, and OR Spectrum. Past consulting clients include the National Audit Office, the Department of Health, the Environment Agency, the Nuclear Decommissioning Authority and the Global Fund to Fight AIDS, Tuberculosis & Malaria. His papers have won awards from the International Society for Pharmacoeconomics and Outcomes Research and the Society for Risk Analysis, and his recent book Portfolio Decision Analysis with Jeff Keisler and Ahti Salo won the INFORMS Decision Analysis Society publication award. Find out more: http://www.strath.ac.uk/mansci/staff/mortonalecmr/

Justus Wesseler Partner Technical University Munich

Prof J. Wesseler is an international expert on valuation under uncertainty and irreversibility. He is the coordinator of the FP7 project PRICE and Scientific Advisory Board member of the, Wissenschafts Campus Halle – Plant based Bioeconomy and the KAITEKI Institute.

EFPIA Participants

Taimur Bhatti Participant Hoffmann-La Roche

Taimur Bhatti is an International Payer Strategy Leader at Hoffmann-La Roche based in Basel, Switzerland. He has 10 years of experience in health economics, health technology assessment, pricing & market access and payer strategy. Prior to his work in oncology and infectious diseases at Roche, Taimur worked at IMS Health in Sydney, Australia and the Ontario Ministry of Health and Long-Term Care in Canada

focusing on several therapeutic areas in both medical devices and pharmaceuticals. He holds a Bachelor of Science in Biomedical Engineering from Duke University, USA and a Masters in Science in Health Economics/Pharmaceutical Sciences from University of Toronto, Canada. Find out more: https://www.linkedin.com/profile/view?id=11765793

http://www.health.org.uk/areas-of-work/programmes/star/

http://www.springer.com/business+%26+management/operations+research/book/978-1-4419-9942-9

http://www.strath.ac.uk/mansci/staff/mortonalecmr/

https://www.linkedin.com/profile/view?id=11765793

To Top

Harpal Dhillon Participant MSD/Merck & Co. Ltd.


Cheryl Donnelly Participant MSD/Merck & Co. Ltd.


Jonathan Goodall Participant AstraZeneca AB

Jonathan Goodall is the pricing and market access director for AstraZeneca’s antibacterial franchise, with responsibility for pricing and payer funding strategies for AstraZeneca’s brands. Jonathan has worked in pricing and reimbursement for 9 years, with experience across a wide range of brands and geographies. Previous roles within AstraZeneca include Pricing

Implementation Director for LatAm and Asia-Pac and Payer Capabilities lead for LatAm. Jonathan holds a PhD in Biochemistry from the University of Birmingham (UK) focusing on beta-lactamases and antibiotic resistance and has spent several years, principally with Basilea Pharmaceutica, working on the development of new antibiotics before moving into more commercial roles within the industry.

Charles Knirsch Partner Pfizer Ltd.

For photo and biography, please see Work Package 1A.

Richard Lawson Participant AstraZeneca AB


Tim Mepham Participant AstraZeneca AB


To Top

James Ryan Participant AstraZeneca AB


Work Package 2 - Create, test and validate new economic models

Leaders

Christine Årdal Academic Co-lead Norwegian Institute of Public Health

C. Årdal has 20 years’ experience working with access to medicines in

multiple sectors, including health system/insurer, pharmaceutical industry,

pharmacy and national development agency. She leads the “Access to

Medicines/Vaccines” group at the Norwegian Institute of Public Health,

which focuses on improving access to medicines in instances where market

mechanisms are insufficient. This includes advisory services for the

Norwegian Agency for Development Cooperation (Norad), the GAVI Alliance, amongst others as well

as research regarding the implementation of national, regional and global policies to incentivize

innovation as well as accessibility. Årdal previously led Norad’s efforts within the UN Commission on

Life-Saving Commodities for Women and Children. She was also a member of the Secretariat for the

World Health Organization’s Consultative Expert Working Group on Research and Development:

Financing and Coordination.

David Findlay

Academic Co-lead

Glaxosmithkline

D. Findlay graduated with a BSc in neuropsychology. He then held UK sales

and marketing positions in J&J before gaining his MBA, majoring in

business strategy. Then moving to Glaxo and eventually GSK, David worked

in the UK operating company, before developing his experience in the US,

located with the GSK antibacterial R&D and leading global commercial

strategy for the pipeline and marketed antibacterial portfolio. Returning to

the UK, David then focussed on antibacterial strategy for pipeline antibiotics, becoming involved in

the evolving landscape of new economic models for incentivising antibacterial R&D. As an EFPIA

representative on DRIVE-AB, David co-leads Work Package 2 (WP2) and is deputy co-ordinator on

DRIVE-AB.

To Top

Francesco Ciabushi Academic Co-lead Uppsala University

Dr F. Ciabuschi is a professor in International Business (IB), member of the Uppsala-IB research group (among the top-10 IB research groups in the world). During the years he has been visiting many important international institutions such as INSEAD, Bologna University, Stanford University and the UNCTAD center (United Nations). Prof. Ciabuschi has been also the Research Director and Deputy head of departemnt for theDepartment

of Business Studies at the Uppsala University. Ciabuschi with 15 years of international research projects experience is an expert in international business, management of multinational corporations, corporate strategy, global value chains, innovation and knowledge management, and state owned enterprises. He has published in many international journals and books (in the areas of e.g., international business, multinational corporations and SMEs management, entrepreneurship, innovation management, knowledge management, strategy, industrial marketing, innovation and technology management). Ciabuschi has received many nominations and awards from different associations such as Academy of Management, Academy of International Business, and the Strategic Society. Find out more: http://www.fek.uu.se/institutionen/person.asp?personId=266&lang=e


Friha Aftab Participant Norwegian Institute of Public Health, University of Oslo


Enrico Baraldi Participant Uppsala University

Prof E. Baraldi is Professor of industrial engineering and management at Uppsala University. He has 15 years of experience as researcher and consultant in the area of business and product development in complex inter-organizational networks from several industries (information and communication technology, biotech, medtech, furniture, automotive, etc.). Next to value and supply chain analysis he specializes also in the field of

innovation management and strategy development. Another major area of concern in his research is the diffusion and commercialization of science, with for instance an ongoing comparison of Uppsala University and Karolinska Institute’s innovation strategies. He is also engaged as ongoing evaluator of EU’s Regional Development Fund projects in the area of med-tech private-public partnerships and university commercialization strategies. The three projects he has recently evaluated range in the span between 2 and 4 Million Euro.

http://www.fek.uu.se/institutionen/person.asp?personId=266&lang=e

To Top

Otto Cars Partner Uppsala University

Prof O. Cars is a senior professor in Infectious Diseases at Uppsala University, Sweden. He has more than 20 years of experience of working on antibiotic resistance. He runs a research laboratory focussing on in vitro pharmacodynamics of antibiotics and antibiotic combinations for MDR bacteria. In 1995, he founded the Swedish Strategic Programme Against Antibiotic Resistance (Strama) for which he was chairman until 2011. In 2004, he initiated the international network Action on Antibiotic Resistance

(ReAct), where he holds the position as senior adviser.

Bengt Domeij Partner Uppsala University


Suzanne Edwards Participant University of Geneva


Dusan Jasovsky Participant Uppsala University


Jostein Johnsen Participant Norwegian Institute of Public Health


To Top

Cecilia Kållberg Participant Norwegian Institute of Public Health

Cecilia Kållberg (MD) is a medical doctor and works at the Department of International Public Health at the Norwegian Institute of Public Health. Within DRIVE-AB, WP2 she will research responsible use policies and their impact on the market and write her PhD on the same topic. She has experience from working with antibiotic resistance through her medical studies where she wrote her medical thesis on “Medical students’ views

on the current and future antibiotic resistance situation” with supervisors from the ReAct- Action on Antibiotic Resistance network. She has also conducted numerous workshops on the same topic, communicating the problems of antibiotic resistance to medical students’ worldwide.

Carl Anderson Kronlid Participant Uppsala University

Carl Anderson Kronlid is a PhD student at Uppsala University under the supervision of Enrico Baraldi (primary supervisor) and Francesco Ciabushi. He has a Master’s degree in industrial management and innovation from Uppsala University. His current research focuses on how different kinds of collaboration (inter-firm, PPP and open source) can foster innovation and how these collaborations are managed. Within the context of DRIVE-AB, this will contribute to the building of the agent-based model in Work Package 2, “creation and testing of new economic models”.

David Kronlid Participant Uppsala University


Olof Lindahl Participant Uppsala University

Lindahl is a researcher in International Business at the Department of Business Studies, Uppsala University. His work concerns challenges that multinational firms face in trying to integrate global R&D through the transfer of innovation processes from headquarters to internationally dispersed R&D sites. Additional areas of interest include management of multinational corporations, corporate strategy, and international

knowledge management, particularly in relation to innovation and technology. For his work Lindahl was nominated for the Haynes Prize for Most Promising Scholar at the Academy of International Business annual conference 2013.

To Top

Steve McKeever Participant Uppsala University

S. McKeever is an Associate Professor in Information Systems at Uppsala University. He has a background in rigorous software engineering, beginning with tools to generate languages for both hardware and software systems. For the last 10 years he has been collaborating with biochemical and physiological modelling communities to exploit computing science

techniques in such domains. He has been involved in BBSRC and EU based modelling projects looking at atomistic simulations; notations for describing heart models and their repositories; and interoperable tumour modelling platforms. He is a reviewer for a number of academic modelling publications, which encompass a wide range of application areas. He completed his undergraduate and masters studies at the University of London, and his doctorate from Oxford University.

Chantal Morel Participant London School of Economics and University of Geneva

Ch. Morel is a health economist with vast experience in analyzing financial incentives for promoting pharmaceutical R&D, including for antibiotics. Morel has also done extensive work (including PhD, numerous publications) in the area of pharmaceutical pricing and regulation. Recently Morel completed an extensive review of the diagnostics market – an analysis of economic and systems-related bottlenecks affecting the supply and demand for diagnostics specifically intended to improve antibiotic prescribing.

Elias Mossialos Partner London School of Economics and University of Geneva

E. Mossialos is Brian Abel-Smith Professor of Health Policy at the Department of Social Policy at the London School of Economics and Political Science, and Director of LSE Health. He is analysing incentives to address the need for sufficient investment in the development of antibiotics in order to meet changing medical needs. He has more than 200 publications in the fields of economics, political science, public policy and health policy. In 2010 he was awarded the Andrija Stampar medal by the Association of Schools of Public Health in Europe (ASPHER) and the European Public Health Association (EUPHA), for contributions to European public health. He was the 2002 and 2007 recipient of the Baxter Award from the European Health Management Association for the best publication in health policy and management in Europe and received the Certificate of Distinguished Submission for the Baxter Award in 2000. In 2002 he received a Commended Prize by the BMA Medical Book Competition. In 2009, under his directorship, LSE Health and Social Care was honoured with the prestigious Queen's Anniversary Prize for Higher and Further Education, which is awarded biennially in recognition of outstanding achievement and excellence in UK universities and colleges.

To Top

Christopher Okhravi Participant Uppsala University

Christopher Okhravi is a PhD student and Junior Lecturer, of Informatics at Uppsala University, Sweden. Using computers, he is currently attempting to simulate the effects of policy on innovation, responsible use and global access of novel antibiotics. Christopher has competed in Microsoft Imagine Cup, been employed in the advertising industry, and has run an indie game development firm. Within DRIVE-AB he is focused on the construction of the computer-aided simulation software, in close cooperation with the rest

of the team from Uppsala, Sweden. Find out more: http://christopherokhravi.se/

Kevin Outterson External Partner Boston School of Law and Chatham House Prof Kevin Outterson, J.D., LL.M, professor and N. Neal Pike Scholar in Health and Disability Law, teaches health law and corporate law at Boston University, where he co-directs the Health Law Program.

His research work focuses on the organization and finance of the health sector. Areas of specialization include global pharmaceutical markets, particularly antibiotics and other antimicrobials that can degrade in usefulness over time through resistance. He leads an interdisciplinary project on the legal ecology of antimicrobial resistance, originally funded by the Robert Wood Johnson Foundation program on public health law. He is an Associate Fellow at the Royal Institute of International Affairs (Chatham House) and a founding member of the Antimicrobial Resistance Working Group at the CDC. He was a senior consultant on the Eastern Research Group study on antibiotic markets for FDA/HHS. Starting in October 2014, he joined DRIVE-AB, a three-year €9 million project on antibiotic business models sponsored by the European Union’s Innovative Medicines Initiative. Professor Outterson also serves on the Advisory Panel for the Longitude Prize for an inexpensive rapid point-of-care antibiotic diagnostic.

He serves as the Editor-in-Chief of the Journal of Law, Medicine & Ethics; faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section on Law, Medicine & Health Care of the AALS; and a member of the Board of the American Society of Law, Medicine & Ethics. Professor Outterson is an occasional author for the New England Journal of Medicine on health law topics. Find out more: www.theincidentaleconomist.com; http://www.bu.edu/law/faculty/profiles/bios/full-time/outterson_k.html

Elizabeth Peacocke Participant Norwegian Institute of Public Health


http://christopherokhravi.se/

http://www.theincidentaleconomist.com/

http://www.bu.edu/law/faculty/profiles/bios/full-time/outterson_k.html

To Top

Stefan Peterson Participant Uppsala University


Jens Plahte Participant Norwegian Institute of Public Health

Jens Plahte (MA, PhD) is trained in Development Geography and Innovation Studies, and is an expert on pharmaceutical policies in a global health perspective. He works as a Senior Advisor at the Department of International Public Health at the Norwegian Institute of Public Health. Previous affiliations are with the Norwegian Biotechnology Advisory Board and the Centre for Technology, Innovation and Culture at the University of Oslo. He has also worked in education and as an independent consultant. He

is also involved in a work package on antimicrobial resistance in the i4C project. Find out more: http://globalstrategy.ninja/i4c/antimicrobials]

Matthew Renwick Participant London School of Economics and Political Science


Miloje Savic Participant Norwegian Institute of Public Health


http://globalstrategy.ninja/i4c/antimicrobials%5d

To Top

Gustav Sigeman Participant Uppsala University

Gustav Sigeman, Senior EU Research Officer at the Faculty Office for Social sciences and Humanities at Uppsala University. He is administrative coordinator for FP7-ITN-project REAL (606879) 'Resilience in East African Landscapes: Identifying critical thresholds and sustainable trajectories – past, present and future', involved in FP7 Security project RESPECT (285582) Rules, Expectations & Security through Privacy-Enhanced Convenient Technologies, coordinator Contact for Horizon 2020-project BRAINVIEW,

FP7-projects in Socioeconomic sciences (MIME), Marie Curie (SOCURB, Infant Interaction, NEGARE, RECLAIM, TEMPEA), Environment (HERCULES), Security (PACT), Ideas (CEV) and the Fundamental Rights and Citizenship programme (CharterClick!) Member of reference group associated to the Horizon 2020 Security Programme Committee. In 2011 he was coordinator of a recommendation paper addressed to the Research Commissioner Máire Geoghehan-Quinn entitled 'The role of Social Sciences and humanities in the Common Strategic Framework for future EU Research and Innovation Funding' supported by the European University Association and 25 universities. 12 years’ experience as EU funding specialist at PricewaterhouseCoopers Global Incentives Services. Grant advisory services to municipalities, universities, SMEs, large companies and NGOs. Structural funds (ESF, ERUF), Lifelong Learning Programme, TEN-T, Baltic Sea Programme, FP5-7, Eurostars, Nopef). Find out more: www.linkedin.com/in/gustavsigeman

Anthony So Participant Uppsala University


Live Storehagen Participant Norwegian Institute of Public Health


Alexandra Waluszewski Participant Uppsala University

Alexandra Waluszewski, Professor, Business Studies, Department of Economic History, Uppsala University and Research Director, Uppsala University’s Centre for Science and Technology Studies (Uppsala STS). Alexandra Waluszewski’s research concerns innovation, technological development and industrial renewal and a special interest is devoted to the relation among publicly funded university research and production/use of

knowledge in business and industry, as well as how these processes are construed in economic theory and policy. She has presented her research in a number of international books and journal articles. Find out more: http://katalog.uu.se/empinfo/?id=XX3044

http://www.linkedin.com/in/gustavsigeman

http://katalog.uu.se/empinfo/?id=XX3044

To Top

Anna Zorzet Participant Uppsala University

Anna Zorzet completed her PhD in medical microbiology with a focus on antibiotic resistance at Uppsala University in 2010. She then moved into the policy field when she joined ReAct, Action on Antibiotic Resistance in Jan 2011. Currently she is head of ReAct’s Europe office and coordinates the program on “Gathering and Translating Evidence” - translating

scientific evidence into policy action on national, regional and global levels. Recent publications include work on how to overcome scientific and structural bottlenecks in antibacterial discovery and development and antibiotic use worldwide. She is also working with many regional and international networks on ABR, the WHO and is on the Stakeholder Advisory Board for the EU Joint Programming Initiative on AMR. Find out more about her work: http://www.reactgroup.org/

EFPIA Participants

James Anderson Participant Glaxosmithkline Research and Development


Ad Antonisse Participant Astra Zeneca AB

Ad Antonisse has studied biochemistry/bio-organic chemistry at the University of Nijmegen, the Netherlands. After his study he joined the pharmaceutical industry and worked for different companies in sales/marketing. Since 2001 he is leading the market access/public affairs department of AstraZeneca BV (The Netherlands) and is member of the management team. His team is responsible for HEOR and

pricing/reimbursement for the portfolio of AstraZeneca in The Netherlands. Besides he is responsible for external contacts with government, political parties and other external stakeholders on behalf of AstraZeneca BV. Find out more: https://nl.linkedin.com/pub/ad-antonisse/5/111/573

David Bradshaw Participant Astellas Pharma Europe Ltd.


http://www.reactgroup.org/

https://nl.linkedin.com/pub/ad-antonisse/5/111/573

To Top

Claudie Charbonneau Participant Pfizer Ltd.

Claudie Charbonneau, MS, PhD, Director, Outcomes and Evidence, Global Health and Value, is currently the Team Lead for Anti-Infectives (AI). In this role she is responsible for the oversight and delivery of clinical and economic evidence generated to support pricing, reimbursement, and access across the AI portfolio.

Claudie has over 17 years’ experience in roles of increasing responsibility dealing with both US and global payer systems. In her prior roles at Pfizer,

as part of the Pfizer Canada HEOR team, she successfully developed and implemented numerous HEOR studies and economic models for multiple therapeutic areas including neurology, oncology, respiratory to support commercial, and pricing and reimbursement strategies. In 2005, Claudie moved to NY Head Quarters to support the Oncology Business Unit (OBU) as part of the Global Health Economics and Outcomes Research team. After 5 years, she joined the Outcomes Research Group in the Specialty Care Business Unit (SCBU) to support the AI European Strategy Asset Team by providing leadership on overall strategic development of economic and real-world evidence required to support the access and commercialization of products in the Anti Bacterial and Anti Fungal portfolios for Europe. She has published an extensive number of papers and abstracts, as well as lectured on epidemiology and health economics. Claudie earned her PhD in Biomedical Sciences with an emphasis on Epidemiology and Health Economics from the University of Montreal in Canada. She holds a Master degree in Physiology-Endocrinology from Laval University in Quebec City.

Peter Hallerbäck Participant Astra Zeneca AB Peter Hallerback has since mid 2012 held the role as Global Brand Director for several products in the AstraZeneca Infection Franchise. He holds a Bachelor of Economics in Marketing from Malardalens University in Sweden and has 18 years of experience from the Pharmaceutical Industry. Peter presents broad experience from Commercial roles in several therapeutic areas and have during his career had responsibilities for and been leading

cross functional teams on local, regional and global level for products in neuroscience, cardiovascular, diabetes, respiratory and infectious diseases in at all stages of the life cycle.

Silas Holland Participant MSD/Merck & Co. Ltd.


To Top

Ka Lum Participant Hoffmann-La Roche

Ka has 17 years of biotech/pharmaceutical experience in the area of new product planning, disease area strategy, portfolio management, sales strategy and pricing & market access. She is currently the Head of Global Pricing & Market Access of Immunology, Infectious Diseases and Ophthalmology at Roche. Her prior roles at Roche include Senior Disease Area Director, Infectious Diseases and Head of Pipeline and Portfolio Planning in Immunology, Infectious Diseases and Ophthalmology.

Prior to Roche, Ka led the New Product Planning group at Jazz Pharmaceuticals, a specialty pharmaceutical company in Palo Alto, where her group was responsible for strategic planning activities of over 10 development programs, and identifying new disease areas for investment. Prior to Jazz, Ka led the forecasting practice at ZS Associates, a global pharmaceutical and biotech consulting firm. Her clients included many of the top pharmaceutical and biotech companies in US, Europe and Asia. Ka received her bachelor degrees in Chemistry and Applied Mathematics from University of California at Berkeley. She was a National Science Foundation fellow and received her Ph.D. in Chemistry from UC Berkeley. She is also a Haas (UC Berkeley) MBA graduate.

John McDonald Participant Astellas Pharma Europe Ltd.

BSc (Hons) Biological Sciences, Durham University, 1984 PhD Physiology, London University, 1988 25 years experience in Development and Commercial roles in pharmaceutical industry, 20 in a Business Development and Commercial function. Extensive experience of commercial assessment and forecasting in the anti-infective field.

Erik Meinhardt Participant MSD/Merck & Co. Ltd.


To Top

David Payne Participant Glaxosmithkline Research and Development

David Payne joined GSK in 1990 and he has held various roles in antibacterial R&D including leading a variety of groups at the forefront of exploiting bacterial genomics that pursued >70 novel antibacterial targets and strategies. He has been the AB DPU head since 2009. David played a key role in integrating public private partnerships as a viable model for GSKs antibacterial R&D having secured substantial external funding from DTRA, BARDA and the Wellcome Trust. Recently, David played a major role in establishing the New Drugs for Bad Bugs Innovative Medicines Initiative which is a €224M program between other pharmaceutical companies and academia. David holds a BSc in Biochemistry from Brunel University, UK and a PhD and DSc from The Medical School, University of Edinburgh, UK and authored more than 90 papers and given over 90 conference presentations on antibacterial R&D.

Rik Rankin Participant Glaxosmithkline

Mr Rankin has been working in the pharmaceutical industry for over 25 years gaining broad based experience in various roles including global commercial strategy, product marketing, health economics, medical communications and research. For the last 15 years he has been working in the Global Commercial Strategy function gaining a breadth of experience and particularly in providing commercial insight to discovery and clinical

development in various Research and Development teams. Rik is currently the Global Marketing Director for infectious Disease with responsibility for the antibacterial, antiviral and Diseases of the Developing World portfolio. He is based at the GSK office at Stockley Park, Uxbridge in the UK.

Kellie Ryan Participant Astra Zeneca AB

Kellie Ryan has an MPH in Epidemiology from the University of Michigan. After graduating, she worked at Covance Market Access Services consulting with pharmaceutical, biotech, and medical device companies on how to establish evidence-based value of products and develop detailed market access and reimbursement strategies across a variety of therapy areas including oncology, nephrology, dermatology, rheumatology, neurology, and

infectious diseases. Kellie joined MedImmune in 2009 where she most recently led the Health Outcomes and Pharmacoeconomics team in infectious disease and vaccines accountable for global payer/reimbursement strategy and implementation of health outcomes and pharmacoeconomic strategy for marketed and pipeline products. In 2013, she became a Global Payer Evidence Director in AstraZeneca supporting the MedImmune ID pipeline and ceftazidime-avibactam (CAZ-AVI). She has been a Global Pricing and Reimbursement Director within AstraZeneca supporting the MedImmune ID antibacterial pipeline and AstraZeneca’s CAZ-AVI since 2014.

Paul Schaper Participant MSD/Merck & Co. Ltd.


To Top

Work Package 3 - Manage the project and its stakeholder platform

Work Package 3A Objective: Coordinate and manage the project

Leaders

Stephan Harbarth Project Coordinator Academic Lead (WP3A) University of Geneva Prof Stephan Harbarth earned in 1993 his medical degree from Ludwig-Maximilians-University in Munich, Germany, and completed his residency in internal medicine and tropical medicine at Munich University Hospitals. After serving as a clinical fellow in the Infectious Diseases Division in the Department of Internal Medicine at Geneva University Hospitals, Dr

Harbarth completed his master’s degree in epidemiology at Harvard University in Boston. He is board certified in infectious diseases and was appointed associate professor at the University of Geneva in 2010. Dr Harbarth’s work has garnered several awards. His group is currently conducting several clinical and epidemiological studies to evaluate key questions related to the control of the acquisition, transmission and infection by multidrug-resistant microorganisms. He participates in several ongoing large-scale EU-funded studies (R-GNOSIS, AIDA, COMBACTE) and manages the DRIVE-AB project to address this public health threat.

Judith Hackett Project Coordinator EFPIA Lead (WP3A) Astra Zeneca AB

Mrs Judy Hackett received her Pharmacy Degree from the University of Toronto. She subsequently completed her M.B.A. at York University. As well she has a graduate degree in Evaluation and Outcomes from the Faculty of Medicine, University of Toronto. She began her career working in community pharmacy and then went onto work as a payer where she developed and managed drug formularies as well as evaluated DUR

reports. She has worked for over 20 years in the pharmaceutical industry in the government affairs, health economics and pricing. Judy is currently Global Payer Evidence Director at AstraZeneca

To Top


Esther Bettiol Participant University of Geneva

Dr E. Bettiol, MD, PhD, is a physician with a research background in medical microbiology and clinical development. She graduated from the University of Geneva in 2001 with a medical degree and obtained in 2006 a PhD in cell biology from the same university. After a post-doctoral experience at New York University working on malaria and Chagas disease, she worked for 4

years in clinical development in the pharmaceutical industry as a medical director, where she acquired skills in project management and multidisciplinary team work. She has been working with Prof Stephan Harbarth at the Geneva University Hospitals and Faculty of Medicine since 2013 doing research and supporting the coordination of several IMI ND4BB projects including COMBACTE’s WP4 STAT-Net and DRIVE-AB.

Fabricio Jantarada Participant University of Geneva

F. Jantarada has a BA in Marketing and is a project manager experienced in operational management of large EU-funded collaborative FP7 projects. In the past years, he has also provided support to Swiss-funded projects coordinated by the Infection Prevention Programm at University of Geneva

Hospitals. In the last year, he has acquired solid knowledge of IMI and H2020 projects, working part-time as a scientific collaborator at Euresearch/UniGe, the Unige European Grants office which supports Unige researchers for all matters regarding European research grants (from preparation to submission, execution and closing as well as contract preparation support).

EFPIA Participants

Juliana Mok Participant AstraZeneca AB

No biography available.

Dana Mastrangelo Participant AstraZeneca AB


To Top

Work Package 3B Objective: Stakeholder platform and external communication

Leaders Ursula Theuretzbacher Academic Lead Centre for Anti-Infective Agents

Dr Theuretzbacher is founder and principal of the Center for Anti-Infective Agents in Vienna, Austria, since 1988. A microbiologist by training, she dedicated her professional life to antibacterial drug R&D as well as optimized usage of these drugs. She is currently work package leader in the multinational collaborative EU funded project AIDA (Re-developing old antibiotics) and in the multinational public-private partnership project

DRIVE-AB (Incentivizing antibacterial drug R&D, funded by the EU Innovative Medicines Initiative=IMI) and partner in the IMI project COMBACTE-MAGNET (Developing new molecules against Gram-Negative Infections). Ursula Theuretzbacher is currently President of the Society of Anti‐Infective Pharmacology (ISAP) and Founding President of the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) PK/PD of Anti‐Infectives Study Group (EPASG). She is chair of a policy and scientific study group of the International Society of Chemotherapy (ISC), Member of the Executive Committee of the International Society of Infectious Diseases (ISID) and member of the ECCMID Programme Committee. Find out more: www.utheuretzbacher.com

Nicole Mahoney EFPIA Lead MSD (formerly Cubist Pharmaceuticals GMBH) Nicole Mahoney is the Director of Global Government Affairs & Regulatory Policy at MSD, where she focuses on U.S. and international regulatory policy, with a particular emphasis on antibiotics and resistance. She works with a variety of stakeholders to spur antibiotic development and represents MSD on the Innovative Medicines Initiative DRIVE AB Project, a

joint undertaking by the EU and European Pharmaceutical Industry Association. Prior to joining Cubist, Nicole served as the senior officer for the Pew Charitable Trusts' antibiotics and innovation project. She also served as a U.S. Food and Drug Administration Commissioner’s Fellow in the FDA’s Office of Antimicrobial Products, analyzing trends in the regulatory process for all new antibiotics reviewed by the agency over three decades. Nicole earned her PhD in biochemistry from the Albert Einstein College of Medicine and completed postdoctoral training at the University of California, San Francisco.

http://www.utheuretzbacher.com/

To Top


Nicholas Brown Participant British Society for Antimicrobial Chemotherapy

Dr Nicholas Brown, MBChB, MA, MD, FRCP(London), FRCPath, is a Consultant Medical Microbiologist at Addenbrooke’s Hospital in Cambridge and an Associate Lecturer at the University of Cambridge. He is employed by Public Health England (PHE) and is currently interim Lead Public Health Microbiologist for the East of England. He is the current President of the British Society for Antimicrobial Chemotherapy (BSAC) (until March 2015). Nick is closely involved with the Antibiotic Action initiative of the BSAC and

is also a member of PHE groups overseeing implementation of the UK Departments of Health strategy to combat antibiotic resistance.

Osman Dar Participant Chatham House


Tracey Guise Participant British Society for Antimicrobial Chemotherapy

Tracey Guise is Chief Executive Officer of the British Society for Antimicrobial Chemotherapy. Tracey began her career in the UK civil service in food science policy and served on the secretariat to the Nuclear Inspection Review Group at the then Ministry of Agriculture, Fisheries and Food. She has worked in healthcare policy, strategy and governance for over 20 years, including working as Deputy Secretary of the Royal College of Paediatrics and Child Health. Tracey currently works alongside the Council of the BSAC to

deliver on the strategic aims of the society that span research, service delivery, education and stakeholder/public in the field of infection management and antimicrobial chemotherapy.

David Heymann Partner Chatham House

Dr David L. Heymann is Professor of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine; Head of the Centre on Global Health Security at Chatham House, London and Chairman of the Board, Public Health England. He was previously the WHO’s Assistant Director-General for Health Security and Environment, and Representative of the Director-General for polio eradication. In 2009 Prof Heymann was appointed an honorary Commander of the Most Excellent Order of the British Empire (CBE) for service to global public health.

To Top

Laura Piddock Participant British Society for Antimicrobial Chemotherapy

Prof Laura Piddock is Professor of Microbiology and Deputy Director of the Institute of Microbiology and Infection at the University of Birmingham, UK. She is the British Society for Antimicrobial Chemotherapy (BSAC) Chair in Public Engagement and Director of Antibiotic Action (www.antibiotic-action.com). Laura started her research career in a clinical environment

and carried out her PhD with Professor Richard Wise at City hospital, Birmingham. Since that time she has been at the forefront of antimicrobial research and has successfully integrated this background with academic research furthering understanding of the mechanisms of antibiotic action and resistance of antibacterial drugs. Her current research crosses the interface of basic research and drug discovery. Laura has published 158 original articles in international peer reviewed journals, 41 invited review articles, 43 research letters, 132 conference proceedings and six chapters in academic books. Her H-index is 56. Laura has received numerous awards and is a Fellow of the Society of Biology, American Society of Microbiology and a member of the Wellcome Trust Peer Review College.

Emma Ross Participant Chatham House


Victoria Wells Participant British Society for Antimicrobial Chemotherapy Victoria Wells, BSc(H), MPH, is a Science Communications Officer at the British Society for Antimicrobial Chemotherapy (BSAC). Victoria kick-started her career in public health by publishing a number of journal articles and earning two public health awards while completing her studies, including the National Collaborating Centre for Environmental Health Student Project Award and the Dr. Robert Clarke Public Health Prize. Since then, Victoria has

worked with the Public Health Agency of Canada as a Data Analysis and Knowledge Translation Officer with the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS), where she gained significant experience in stakeholder engagement and co-authored the annual CIPARS report. Victoria has also completed a public health evaluation of a global health charity in Ghana where upon witnessing local health care practices, her passion and concern for the future of antimicrobial therapies was strengthened. Victoria moved from Canada to the United Kingdom to work with BSAC on the Innovative Medicines Initiative DRIVE AB Project in January, 2015. Find out more: https://ca.linkedin.com/pub/victoria-wells/77/66a/a6a

https://ca.linkedin.com/pub/victoria-wells/77/66a/a6a

To Top

EFPIA Participants

Jonathan Goodall Participant Astra Zeneca AB


Nicky Lilliott Participant Astra Zeneca AB Nicky Lilliott is the Director of Global Policy for the biopharmaceutical company AstraZeneca and is based in the UK. Nicky graduated in chemistry from the University of Kent and has worked in various roles in the pharmaceutical industry. Before joining AstraZeneca, Nicky headed up the Regulatory Policy team at the Association for the British Pharmaceutical Industry and prior to that worked in R&D at SmithKline Beecham (now GSK).

Nicky works with a multidisciplinary team at AstraZeneca to create company positions on key policy topics, including antimicrobial resistance.

Nathalia Murillo Participant Sanofi


Seamus O’Brien Participant Astra Zeneca AB


Kam Pooni Participant Astellas Pharma Europe Ltd. Kam Pooni has enjoyed a progressive 19 year career in the global pharma industry. His award-winning commercial and business development experience spans the acquisition and management of key accounts, leading Market Access requirements into Clinical Development programmes, and driving Market Access Strategy across EMEA Operations for the Anti-

Infectives and Pain franchises. Currently, Kam leads EU, National, Regional and Local Market Access engagement plans, Risk sharing, Integrated Care Pathways, HTAs, and Core Value Development initiatives. He has built and managed large, cohesive Sales, Marketing and CRM teams, and led delivery of ~100 Pan-European projects, including licensing, commercial distribution models, and divestment programmes. A keynote presenter, Kam is based Hampshire, UK.

To Top

Steve Projan Participant Astra Zeneca AB


Donald Trick Participant Glaxosmithkline Biography not available at this time.

André Trottier Participant Hoffmann-La Roche


Marc Wells Participant Astra Zeneca AB Biography not available at this time.

Alex White Participant Hoffmann-La Roche


Documents

The people behind the project - DRIVE-AB